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Background: Despite major advances in prevention and treatment, coronary artery disease
(CAD) remains the leading cause of death worldwide. Whereas many sources of data are availa-
ble on the epidemiology of acute coronary syndromes, fewer datasets reflect the contemporary
management and outcomes of stable CAD patients.
Hypothesis: A worldwide contemporary registry would improve our knowledge about stable
CAD. The main objectives are to describe the demographics, clinical profile, contemporary man-
agement and outcomes of outpatients with stable CAD; to identify gaps between evidence and
treatment; and to investigate long-term prognostic determinants.
Methods: CLARIFY (ProspeCtive observational LongitudinAl RegIstry oF patients with stable
coronary arterY disease) is an ongoing international observational longitudinal registry. Stable
CAD patients from 45 countries in Europe, Asia, America, Middle East, Australia and Africa
were enrolled between November 2009 and June 2010. The inclusion criteria were previous
myocardial infarction, evidence of coronary stenosis >50%, proven symptomatic myocardial
ischemia or prior revascularization procedure. The main exclusion criteria were serious non-car-
diovascular disease, conditions interfering with life expectancy or severe other cardiovascular
disease (including advanced heart failure). Follow-up visits were planned annually for up to 5
years, interspersed with 6-month telephone calls.
Results: Of the 32,703 patients enrolled, most (77.6%) were male, age (mean  SD) was
64.2  10.5 years, and 71.0% were receiving treatment for hypertension; mean  SD resting
heart rate was 68.2  10.6 bpm. Patients were enrolled based on a history of myocardial
infarction >3 months earlier (57.7%), having at least one stenosis >50% on coronary angiogra-
phy (61.1%), proven symptomatic myocardial ischemia on non-invasive testing (23.1%), or his-
tory of percutaneous coronary intervention or coronary artery bypass graft (69.8%). Baseline
characteristics were similar across the four subgroups identified by the four inclusion criteria.
Conclusion: CLARIFY will provide a useful resource for understanding the current epidemiology
of stable CAD.
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1 | INTRODUCTION
Despite major advances in the prevention and treatment of athero-
thrombosis, coronary artery disease (CAD) is the primary cause of
mortality worldwide, continues to be a major burden on public
health,1,2 and is expected to remain the world’s leading cause of mor-
bidity and mortality in 2020.3 The number of patients with CAD is
likely to rise as life expectancy increases, as the prevalences of diabe-
tes mellitus (DM) and obesity increase, and due to the improved sur-
vival of patients presenting with an acute coronary syndrome.4
The clinical characteristics, cardiovascular (CV) risk factors, treat-
ment, and outcomes of patients with CAD have changed markedly
over the years. Most of the existing data regarding the epidemiology
of CAD are relatively old, often focus on 1 manifestation of disease
(eg, stable angina)5 or pertain to acute coronary syndromes,6 and are
often restricted to a single country or a specific geographic region,
particularly North America or Western Europe.7–9 Thus, there is a
need for robust contemporary data in stable CAD representing >1
region and addressing more than symptomatic angina. Moreover,
despite the importance of heart rate (HR) in the prognosis of stable
CAD,10–14 HR is not a routine component of CV risk assessment, nor
a tool to decide whether treatment is indicated, and most datasets
have not collected detailed information on HR in stable CAD.
Large datasets are available from randomized trials in stable
CAD. However, although these are the gold standard to evaluate
new therapies,15 they are generally performed in highly selected
populations that often do not reflect patients encountered in daily
practice in terms of their clinical characteristics, comorbidities, socio-
economic status, management, and outcomes.16 Large prospective
registries often provide a more realistic description of the patients’
actual characteristics, management, and outcomes, provided their
recruitment is unbiased and the sample size is sufficiently large.17,18
The prospeCtive observational LongitudinAl RegIstry oF patients
with stable coronary arterY disease (CLARIFY) was initiated to improve
knowledge about the current management and outcomes of patients
with stable CAD, to assess prognosis, and to subsequently design inter-
ventions to improve evaluation and treatment of these patients.
2 | METHODS
2.1 | Objectives
The first objective was to describe contemporary patients with stable
CAD in terms of their demographic characteristics, clinical profile, man-
agement, and outcomes, with a global geographic reach, encompassing
patients from high-, middle-, and low-income regions. The second
objective was to identify gaps between evidence-based recommenda-
tions and current management. The third objective was to characterize
the clinical determinants of long-term prognosis in this population.
2.2 | Study design
CLARIFY is an ongoing international, prospective, observational, lon-
gitudinal registry of outpatients with stable CAD, with yearly follow-
up for up to 5 years. This observational registry was designed to col-
lect the current status of outpatients with stable CAD, including their
demographic characteristics, clinical profiles, therapeutic strategies,
and outcomes. Data were collected prospectively at annual visits
every 12  3 months. Owing to substantial geographic variations in
the epidemiology of stable CAD, this registry is international to gen-
erate reliable data on several regions in the world. Patients were
enrolled in 45 countries in Europe, Asia, North/Central/South Amer-
ica, the Middle East, Australia, and South Africa (Figure 1).
FIGURE 1 Worldwide distribution of study participants (n = 32703).
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Importantly, no patients were enrolled in the United States, due to a
lack of sponsor support.
The study was performed in accordance with the principles laid
out in the Declaration of Helsinki; in the United Kingdom, it was
approved by the national Research Ethics Service, Isle of Wight,
Portsmouth, and Southeast Hampshire Research Ethics Committee.
Local ethical approval was also obtained in all 45 countries before
recruitment, according to national and local regulations at each site.
All patients gave written informed consent.
The CLARIFY Registry is registered in the ISRCTN registry of
clinical trials (ISRCTN43070564). For a complete list of CLARIFY Reg-
istry investigators, see Supporting Information, Appendix, in the
online version of this article.
2.3 | Study population
Patients were eligible for enrollment if they fulfilled ≥1 of the follow-
ing (not mutually exclusive) criteria: documented myocardial infarc-
tion (MI) >3 months ago; coronary angiography showing ≥1 coronary
stenosis of >50%; chest pain with myocardial ischemia proven by
stress electrocardiography (ECG), stress echocardiography, or myo-
cardial imaging; and coronary artery bypass grafting (CABG) or percu-
taneous coronary intervention (PCI) >3 months ago. The exclusion
criteria were hospitalization for CV disease within the previous
3 months (including revascularization); planned revascularization; and
conditions that could have affected participation or 5-year follow-up,
such as limited cooperation, limited legal capacity, serious non-CV
disease, conditions interfering with life expectancy (eg, cancer, drug
abuse), severe CV disease (eg, advanced heart failure [HF]), severe
valve disease, and history of valve repair/replacement. The first
patient was included on November 26, 2009, and recruitment was
completed on June 30, 2010.
2.4 | Site selection
To ensure that the enrolled population of outpatients with stable
CAD was representative of the population of each country, sites
were identified based on a predefined selection of physicians includ-
ing cardiologists, general practitioners, internists, and hospital-based
physicians. In each country, selection of physicians was made by
national coordinators using the best available epidemiological data
reflecting the burden of CAD in that country, to provide a represen-
tative distribution of physicians across regions and location types
(ie, urban, suburban, and rural areas). Epidemiologic and medical care
data, published and endorsed by national or international societies,
either local or regional, were used to identify the distribution of coro-
nary patients in each country, to select physician types and locations,
and subsequently patients. The executive committee validated the
physician selection process for each country before starting enroll-
ment. As an observational registry, physicians were instructed to
manage their patients per usual practice, and no specific tests or
therapies were prescribed as part of the registry, to ensure that
patient care was not affected by participation in the study.
A total of 2898 physicians were selected. Each physician was
requested to recruit 10 to 15 consecutive outpatients with stable
CAD. In each country, the goal was to meet a predefined country tar-
get of approximately 25 patients per million inhabitants (range,
12.5–50) to ensure balanced representation of participating coun-
tries; one exception was China, where recruitment was expected to
be representative of the fraction of the population having access to
“Western-type” medical care. Patients were enrolled over a brief
period to minimize the risk of selection bias.
2.5 | Data collection and evaluation
Data were collected anonymously using electronic standardized inter-
national case-report forms (translated into the local language) at
baseline and annually for up to 5 years, to ascertain clinical events,
hospitalization, employment status, or sick leave. Between the base-
line visit and each annual visit, to maximize follow-up and retention
rates, 6-month telephone calls were made to collect vital status, con-
firm contact details, and ensure the next annual visit was planned.
At baseline, data collection included demographic data (sex, age,
living status, employment status), risk factors and lifestyle, medical
history, physical examination, and vital signs, including sitting arterial
blood pressure (BP) and HR (determined by both pulse palpation and
12-lead ECG performed within the previous 6 months), current symp-
toms and, if available, results of biological tests performed within the
previous 12 months (fasting blood glucose; hemoglobin A1c; total
cholesterol, high-density lipoprotein cholesterol, and low-density lipo-
protein cholesterol; triglycerides; serum creatinine; and hemoglobin),
measurement of left ventricular ejection fraction (LVEF), and results
of coronary angiography and noninvasive stress tests. Finally, detailed
current drug treatment data were collected by type of agent (without
dosages, except for β-blockers).
Missing institutional review 
board approval or consent 
(n = 329)
Patients enrolled (n = 33,032)




(n = 18,876; 57.7%)
Coronary angiography 
showing ≥1 coronary 
stenosis >50%*
(n = 19,996; 61.1%)
Chest pain with myocardial ischemia 
proven by stress ECG, stress 
echocardiography or myocardial imaging*
(n = 7544; 23.1%)
PCI or CABG 
(>3 months ago)*
(n = 22,836; 69.8%)
FIGURE 2 Study flow diagram. Abbreviations:
CABG, coronary artery bypass graft; ECG,
electrocardiogram; PCI, percutaneous coronary
intervention. * Groups are not mutually exclusive.
SORBETS ET AL 3
TABLE 1 Baseline clinical parameters
All CLARIFY Patients,
n = 32 703
Prior MI >3 Months









n = 7544 (23.1%)
History of PCI or
CABG >3 Months
Ago,a n = 22 836
(69.8%)
Age, y 64.2  10.5 63.1  10.7 64.1  10.4 64.6  10.2 64.2  10.4
Male sex 25 365 (77.6) 15 246 (80.8) 15 877 (79.4) 5571 (73.9) 18 291 (80.1)
Ethnicity
Caucasian 21 112 (64.6) 12 873 (68.2) 12 124 (60.6) 4772 (63.3) 14 342 (62.8)
South Asian 2444 (7.5) 1336 (7.1) 1549 (7.7) 539 (7.1) 1645 (7.2)
Chinese 2753 (8.4) 1242 (6.6) 1938 (9.7) 330 (4.4) 2040 (8.9)
Japanese/Korean 1035 (3.2) 401 (2.1) 685 (3.4) 103 (1.4) 853 (3.7)
Hispanic 1624 (5.0) 1008 (5.3) 1058 (5.3) 580 (7.7) 1171 (5.1)
Black/African 357 (1.1) 247 (1.3) 217 (1.1) 94 (1.2) 225 (1.0)
Unknown 3378 (10.3) 1769 (9.4) 2425 (12.1) 1126 (14.9) 2560 (11.2)
BMI, kg/m2 27.3 (24.8–30.4) 27.5 (25.0–30.5) 27.2 (24.8–30.1) 27.6 (25.0–30.5) 27.2 (24.8–30.1)
Waist circumference, cm 97 (89–105) 97 (89–105) 97 (89–105) 97 (89–105) 97 (89–105)
Family history of premature
CAD
9326 (28.5) 5503 (29.2) 5621 (28.1) 2576 (34.2) 6443 (28.2)
Treated hypertension 23 210 (71.0) 13 029 (69.1) 14 231 (71.2) 5619 (74.5) 16 122 (70.6)
DM 9502 (29.1) 5388 (28.6) 5956 (29.8) 2277 (30.2) 6799 (29.8)
Dyslipidemia 24 504 (74.9) 14 383 (76.2) 15 318 (76.6) 5991 (79.5) 17 465 (76.5)
Smoking status
Current 4077 (12.5) 2700 (14.3) 2391 (12.0) 870 (11.5) 2706 (11.9)
Former 15 109 (46.2) 9263 (49.1) 9570 (47.9) 3281 (43.5) 11 038 (48.3)
Never 13 513 (41.3) 6911 (36.6) 8032 (40.2) 3391 (45.0) 9088 (39.8)
Alcohol intake (drinks per
week)b
0 15 613 (47.8) 8813 (46.7) 9562 (47.8) 3451 (45.8) 10 797 (47.3)
1–19 15 898 (48.6) 9305 (49.3) 9743 (48.7) 3778 (50.1) 11 269 (49.4)
20–40 1068 (3.3) 688 (3.6) 617 (3.1) 279 (3.7) 684 (3.0)
>40 113 (0.3) 67 (0.4) 65 (0.3) 29 (0.4) 75 (0.3)
Stimulant drinks consumed
Coffee 15 500 (47.4) 8842 (46.9) 9642 (48.3) 3502 (46.6) 11 438 (50.1)
Tea 10 040 (30.7) 6247 (33.1) 5594 (28.0) 2254 (30.0) 6195 (27.2)
Neither 7129 (21.8) 3774 (20.0) 4733 (23.7) 1763 (23.4) 5178 (22.7)
Intake of stimulant drinks,
cups/d
2 (2–4) 2 (2–4) 2 (2–4) 2 (2–4) 2 (2–4)
Employment status
Employed full-time 7980 (24.4) 4955 (26.3) 5038 (25.2) 1814 (24.1) 5659 (24.8)
Employed part-time 2266 (6.9) 1435 (7.6) 1284 (6.4) 520 (6.9) 1471 (6.4)
Unable to work 1284 (3.9) 902 (4.8) 802 (4.0) 337 (4.5) 846 (3.7)
Unemployed 1852 (5.7) 1079 (5.7) 1062 (5.3) 400 (5.3) 1234 (5.4)
Retired 18 081 (55.3) 9860 (52.2) 10 979 (54.9) 4173 (55.4) 12 721 (55.7)
Other 1232 (3.8) 640 (3.4) 824 (4.1) 294 (3.9) 897 (3.9)
Weekly physical activity
None 5287 (16.2) 2899 (15.4) 3094 (15.5) 1323 (17.6) 3640 (15.9)
Light activity most weeks 16 810 (51.4) 9970 (52.8) 10 071 (50.4) 3821 (50.7) 11 264 (49.4)
≥20 minutes vigorous
activity 1–2 times per
week
5470 (16.7) 3130 (16.6) 3432 (17.2) 1277 (16.9) 3968 (17.4)
≥20 minutes vigorous
activity ≥3 times per
week
5121 (15.7) 2870 (15.2) 3387 (16.9) 1115 (14.8) 3950 (17.3)
Education level
Primary school (or less) 8648 (26.5) 4836 (25.6) 5495 (27.5) 1972 (26.2) 6245 (27.4)
(Continued )
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At annual follow-up visits, data were collected on clinical out-
comes since the last visit, demographic data, new physical examina-
tion and vital signs including HR, current symptoms, most recent
available measurements, and medical treatments.
2.6 | Outcomes
The main outcomes collected during the 5-year follow-up included
mortality and CV morbidity data. Deaths were categorized into fatal
MI, fatal stroke and other CV death (including sudden death), non-CV
death (death that was not definitely CV), and unknown cause. Events
were collected as reported by investigators without central adjudica-
tion, but investigators were provided within the case-report forms
with a set of definitions for each outcome. Recognizing the difficulty
in assigning definite causes in many cases of outpatient death,
unknown-cause deaths were grouped with other CV deaths for anal-
ysis. Nonfatal events collected were nonfatal MI, unstable angina,
new-onset or worsening HF requiring hospitalization, coronary revas-
cularization (PCI or CABG), nonfatal stroke or transient ischemic
attack, major bleeding, valve repair/replacement, pacemaker implan-
tation, atrial fibrillation/flutter, peripheral artery disease surgery/
amputation/interventions, carotid surgery/stenting, and abdominal
aorta surgery/stenting.
To ensure data quality, every year, 1% of the centers were ran-
domly selected to perform on-site audits. In these selected centers,
100% of the data for all patients were checked for source documen-
tation and accuracy. Data quality control was done at face-to-face
quality-control visits and involved review of source documents sup-
porting the adequacy and accuracy of data collected on the case-
report forms.
2.7 | Statistical analysis
CLARIFY is an observational registry, and the size of the population
was not based on a planned treatment comparison. The number of
patients to be included was computed based on the aim to build a
robust risk model at the completion of follow-up and depended on
the CV event rate, number of subjects lost to follow-up, and study
duration. Based on data from the literature, the annual rates of CV
death and of major adverse CV events were expected to be approxi-
mately 2% and 4.5%, respectively. CLARIFY had to screen ≥31
000 subjects and follow them up for 4 to 5 years (with approximately
5% per year loss to follow-up). With these assumptions, it was
expected that there would be approximately 2300 CV deaths at the
end of follow-up, providing ample power for risk modeling. Taking a
conservative approach, based on the analysis of HR as a categorical
variable (population split by quartiles of HR) comparing risk of CV
death between the highest HR quartile to the other quartiles, there
would be ≥80% power to identify a 20% increase in risk in the group
with the highest HR. If HR was considered as a continuous variable,
there would be 90% power at the 5% level of significance to detect
an underlying hazard ratio of 1.06 per 10-bpm increase in HR.
Data were recorded centrally and analyzed by an academic statis-
tics center (Robertson Centre for Biostatistics, University of Glasgow,
United Kingdom). Baseline results are presented for the overall popu-
lation and for the 4 subgroups identified by their inclusion criteria:
documented MI >3 months ago; coronary angiography showing ≥1
coronary stenosis of >50%; chest pain with myocardial ischemia
proven by stress ECG, stress echocardiography, or myocardial ima-
ging; and CABG or PCI performed >3 months ago. Baseline continu-
ous variables are presented as mean  SD or median and
interquartile range, depending on the distribution of the data; catego-
rical data are presented as counts and percentages. As the 4 patient
groups largely overlap and there was no a priori hypothesis regarding
differences between groups, no formal statistical comparison was
made between these groups given the large number of variables
available for comparison.
3 | RESULTS
A total of 33 032 patients were enrolled in the CLARIFY Registry. Of
these, 329 withdrew their consent or did not meet the inclusion cri-
teria. The baseline study population was therefore 32 703 patients
(Figure 2).
Baseline demographics are detailed in Table 1. The mean age
was 64.2  10.5 years. Patients were predominantly male (77.6%)
and Caucasian (64.6%). The median body mass index was 27.3, indi-
cating that the majority of subjects were overweight or obese. Like-
wise, a majority of patients were either current or former smokers,
dyslipidemic, and treated for hypertension. The majority of the
patients did not work, and most reported only light physical activity.
Overall, based on the 4 main (not mutually exclusive) inclusion
criteria, 57.7% of patients were enrolled on the basis of a medical
TABLE 1 Continued
All CLARIFY Patients,
n = 32 703
Prior MI >3 Months









n = 7544 (23.1%)
History of PCI or
CABG >3 Months
Ago,a n = 22 836
(69.8%)
Secondary school 15 204 (46.5) 8797 (46.6) 9119 (45.6) 3499 (46.4) 10 535 (46.2)
College/university 8841 (27.0) 5238 (27.8) 5373 (26.9) 2065 (27.4) 6046 (26.5)
Abbreviations: BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CLARIFY, Prospective Observational Longitudi-
nal Registry of Patients With Stable Coronary Artery Disease; DM, diabetes mellitus; IQR, interquartile range; MI, myocardial infarction; PCI, percutane-
ous coronary intervention; SD, standard deviation.
Data are presented as n (%), mean  SD, or median (IQR).
a Inclusion criteria are not mutually exclusive; some patients may be included in >1 group.
b 1 drink = 1 standard measure of spirits, 1 glass of wine, 1 bottle of beer.
SORBETS ET AL 5
TABLE 2 Baseline medical history, symptoms, and paraclinical parameters
All CLARIFY
Patients, n = 32 703
Prior MI >3 Months





n = 19 996 (61.1%)
Chest Pain With Proven
Myocardial Ischemia,a
n = 7544 (23.1%)
History of PCI or
CABG >3 Months
Ago,a n = 22 836
(69.8%)
MI 19 595 (59.9) NA 11 521 (57.6) 3219 (42.7) 13 350 (58.5)
PCI 19 162 (58.6) 11 236 (59.5) 13 797 (69.0) 3746 (49.7) NA
CABG 7703 (23.6) 3966 (21.0) 5093 (25.5) 1635 (21.7) NA
AAA 504 (1.5) 300 (1.6) 314 (1.6) 130 (1.7) 384 (1.7)
Carotid disease 2474 (7.6) 1279 (6.8) 1617 (8.1) 725 (9.6) 1806 (7.9)
Internal cardiac defibrillator 418 (1.3) 334 (1.8) 278 (1.4) 74 (1.0) 316 (1.4)
Pacemaker 788 (2.4) 408 (2.2) 503 (2.5) 197 (2.6) 565 (2.5)
TIA 1001 (3.1) 522 (2.8) 580 (2.9) 327 (4.3) 624 (2.7)
Hospitalization for CHF 1531 (4.7) 1051 (5.6) 914 (4.6) 391 (5.2) 941 (4.1)
Current or previous clinical trial
participation
1135 (3.5) 778 (4.1) 663 (3.3) 270 (3.6) 760 (3.3)
Stroke 1314 (4.0) 777 (4.1) 758 (3.8) 300 (4.0) 848 (3.7)
AF/flutter 2313 (7.1) 1190 (6.3) 1369 (6.8) 562 (7.5) 1565 (6.9)
Asthma/COPD 2419 (7.4) 1393 (7.4) 1441 (7.2) 718 (9.5) 1553 (6.8)
PAD 3239 (9.9) 1862 (9.9) 1983 (9.9) 914 (12.1) 2221 (9.7)
Any angina 7212 (22.1) 4423 (23.4) 3675 (18.4) 2541 (33.7) 3553 (15.6)
Angina and CCS class
No angina 25 479 (77.9) 14 446 (76.6) 16 312 (81.6) 4996 (66.3) 19 273 (84.4)
Angina class I 2063 (6.3) 1160 (6.1) 1141 (5.7) 706 (9.4) 1136 (5.0)
Angina class II 3834 (11.7) 2355 (12.5) 1966 (9.8) 1378 (18.3) 1898 (8.3)
Angina class III 1236 (3.8) 863 (4.6) 527 (2.6) 435 (5.8) 477 (2.1)
Angina class IV 78 (0.2) 45 (0.2) 40 (0.2) 21 (0.3) 41 (0.2)
CHF symptoms including
NYHA class
No CHF 27 766 (84.9) 15 328 (81.3) 17 483 (87.5) 6358 (84.4) 20 233 (88.6)
CHF NYHA class II 4113 (12.6) 2953 (15.7) 2131 (10.7) 968 (12.8) 2203 (9.7)
CHF NYHA class III 808 (2.5) 584 (3.1) 369 (1.8) 209 (2.8) 389 (1.7)
HbA1c, % 6.8  1.8 6.9  2.1 6.8  1.9 6.8  1.3 6.8  1.4
Cr, mmol/L 0.088 (0.076–0.102) 0.088 (0.077–0.103) 0.088 (0.076–0.102) 0.088 (0.076–0.102) 0.088 (0.076–0.102)
Hgb, g/dL 14.0 (13.0–15.0) 14.1 (13.1–15.1) 14.1 (13.0–15.0) 14.0 (13.0–15.0) 14.1 (13.0–15.0)
Fasting blood glucose, mmol/L 5.7 (5.1–6.6) 5.7 (5.1–6.6) 5.7 (5.1–6.7) 5.7 (5.1–6.6) 5.7 (5.2–6.7)
TC, mmol/L 4.3 (3.7–5.0) 4.3 (3.7–5.1) 4.2 (3.6–4.9) 4.4 (3.7–5.2) 4.2 (3.6–4.9)
HDL-C, mmol/L 1.1 (1.0–1.4) 1.1 (1.0–1.3) 1.1 (1.0–1.4) 1.2 (1.0–1.4) 1.1 (1.0–1.4)
LDL-C, mmol/L 2.4 (1.9–2.9) 2.4 (1.9–3.0) 2.3 (1.9–2.9) 2.4 (1.9–3.0) 2.3 (1.9–2.9)
Fasting TG, mmol/L 1.4 (1.0–1.9) 1.4 (1.0–1.9) 1.4 (1.0–1.9) 1.4 (1.0–2.0) 1.4 (1.0–1.9)
HR (palpation), bpm 68.2  10.6 68.3  10.6 67.7  10.4 68.4  10.9 67.7  10.3
ECG heart rate, bpm 67.1  11.4 67.2  11.3 66.6  11.1 67.6  11.8 66.5  11.0
SBP, mm Hg 131.0  16.7 130.1  16.6 130.4  16.4 131.8  16.1 130.5  16.4
DBP, mm Hg 77.3  10.0 77.3  10.1 77.0  9.7 77.5  10.0 76.9  9.7
LVEF, % 56.1  11.1 53.7  11.2 56.5  11.0 57.3  10.8 56.4  11.0
Coronary artery territories with
stenosis >50%
LM stem 2848 (8.7) 1485 (7.9) 2014 (10.1) 713 (9.5) 2465 (10.8)
LAD 19 062 (58.3) 10 420 (55.2) 14 022 (70.2) 3965 (52.6) 15 970 (70.0)
LCX 11 793 (36.1) 6547 (34.7) 8920 (44.6) 2595 (34.4) 10 028 (43.9)
RCA 14 233 (43.5) 8320 (44.1) 10617 (53.1) 2982 (39.5) 11 951 (52.4)
Bypass graft 2630 (8.0) 1427 (7.6) 1703 (8.5) 651 (8.6) 2482 (10.9)
No significant stenosis 1057 (3.2) 609 (3.2) 205 (1.0) 417 (5.5) 221 (1.0)
Coronary angiography not
done in the past 12 months
4763 (14.6) 3247 (17.2) 366 (1.8) 1750 (23.2) 520 (2.3)
(Continued )
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history of MI >3 months ago, 61.1% on the basis of having had coro-
nary angiography showing ≥1 coronary stenosis of >50%, 23.1% on
the basis of having experienced chest pain with evidence of myocar-
dial ischemia on noninvasive testing, and 69.8% due to a history of
myocardial revascularization by PCI or CABG.
At the time of enrollment, most patients were asymptomatic,
without symptoms of angina or HF. Mean BP readings were within
the normal range, as were the values for creatinine and fasting blood
glucose (Table 2). Mean resting HR was 68.2  10.6 bpm when
measured by pulse (available in 32 673 patients) and 67.1  11.4
bpm when measured by ECG (available in 24 438 patients), and most
patients were in sinus rhythm. Among the 22 519 patients in whom a
measurement was available, mean LVEF was 56.1%  11.1%. Among
patients with results of coronary angiography within the past
12 months, almost all patients had ≥1 significant coronary stenosis:
58.3% had a significant stenosis localized in the left anterior descend-
ing artery, 36.1% in the left circumflex artery, 43.5% in the right coro-
nary artery, and 8.7% in the left main stem. Of note, 3.2% of patients
with angiographic data had no stenosis >50%.
At baseline, the CLARIFY population had high rates of use of
evidence-based drugs for prevention in CAD (Table 3). Most patients
were receiving aspirin (ASA; 87.8%) and lipid-lowering drugs (92.3%).
Rates of β-blocker, angiotensin-converting enzyme inhibitor (ACEI),
and angiotensin II receptor blocker therapies were 75.3%, 51.7%, and
26.5%, respectively. Three-quarters of patients received either full
(39.2%) or partial (37.7%) reimbursement for their CV agents.
Overall, the clinical characteristics of the 4 groups were similar,
although patients in the group with symptomatic angina were slightly
older, with a higher prevalence of DM, treated hypertension, and dys-
lipidemia, and less physical activity (Table 1). Patients with angina also
more frequently had a history of atrial fibrillation/flutter, peripheral
artery disease, and asthma/chronic obstructive pulmonary disease
(Table 2). Given the size of the cohort, these modest differences were
significant. There were, however, notable differences in management
between groups: patients with a history of MI were more likely to
receive ASA, β-blockers, and ACEIs and less likely to receive calcium
antagonists than the other groups (Table 3). Also, the use of some
non-CV drug classes was substantial (eg, proton pump inhibitors
[24.8%] and anti-DM agents [24.5%]).
4 | DISCUSSION
The CLARIFY Registry enrolled a large, worldwide population repre-
sentative of contemporary established outpatients with CAD. This
population was composed of a relatively young and mostly hyperten-
sive male population, mainly retired, with few current smokers or
patients with DM, with preserved LVEF, and with high rates of use of
evidence-based drugs for secondary prevention. This probably
reflects the exclusion of patients with severe noncardiac conditions
or advanced other cardiac conditions, such as HF or advanced valvu-
lar disease.
Compared with the Euro Heart Survey in 20055 or the REACH
Registry in 200717 and 2010,18 the rates of use of evidence-based
medications for secondary prevention appear to be higher in the
CLARIFY stable-CAD population, reflecting increasing adherence to
international guidelines in routine clinical practice.19–23 Despite this
improvement, prevalence and control of major CV risk factors vary
markedly worldwide, with many outpatients with stable CAD being
treated suboptimally.24
With a very detailed 5-year follow-up—including medical events;
clinical, biological, and paraclinical variables; and medication—the
CLARIFY Registry will provide the opportunity to describe the prog-
nostic determinants of stable CAD. Some preliminary findings from
CLARIFY already have been reported. In patients with hypertension
and stable CAD, systolic BP <120 mm Hg and diastolic BP <70 mm
TABLE 2 Continued
All CLARIFY
Patients, n = 32 703
Prior MI >3 Months





n = 19 996 (61.1%)
Chest Pain With Proven
Myocardial Ischemia,a
n = 7544 (23.1%)
History of PCI or
CABG >3 Months
Ago,a n = 22 836
(69.8%)
ECG rhythm
Sinus rhythm 23 179 (94.9) 13 622 (95.4) 14 694 (95.1) 5375 (94.6) 16 482 (95.2)
AF/flutter 836 (3.4) 427 (3.0) 503 (3.3) 200 (3.5) 537 (3.1)
Paced rhythm 402 (1.6) 227 (1.6) 251 (1.6) 105 (1.8) 288 (1.7)
LBBB 1201 (4.9) 739 (5.2) 724 (4.7) 292 (5.1) 767 (4.4)
Vessel disease
0 1007 (3.6) 576 (3.7) 199 (1.0) 394 (6.8) 213 (1.0)
1 11 458 (41.1) 6498 (41.7) 8059 (41.1) 2001 (34.6) 8783 (39.4)
≥2 15 413 (55.3) 8519 (54.6) 11 341 (57.9) 3383 (58.5) 13 275 (59.6)
Abbreviations: AAA, abdominal aortic aneurysm; AF, atrial fibrillation; CABG, coronary artery bypass grafting; CCS, Canadian Cardiovascular Society;
CHF, chronic heart failure; CLARIFY, Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease; COPD, chronic
obstructive pulmonary disease; Cr, creatinine; DBP, diastolic blood pressure; ECG, electrocardiogram; HbA1c, glycated hemoglobin; HDL-C, high-density
lipoprotein cholesterol; Hgb, hemoglobin; HR, heart rate; IQR, interquartile range; LAD, left anterior descending artery; LBBB, left bundle branch block;
LCX, left circumflex artery; LDL-C, low-density lipoprotein cholesterol; LM, left main coronary artery; LVEF, left ventricular ejection fraction; MI, myocar-
dial infarction; NA, not applicable; NYHA, New York Heart Association; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; RCA,
right coronary artery; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol; TG, triglycerides; TIA, transient ischemic attack.
Data are presented as n (%), mean  SD, or median (IQR).
a Inclusion criteria are not mutually exclusive; some patients may be included in >1 group.
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Hg were each associated with CV events, including mortality, sup-
porting the existence of a J-curve phenomenon and suggesting that
caution should be taken with the use of BP-lowering treatment in
patients with hypertension and CAD.25
Despite high rates of use of β-blockers, patients with stable CAD
often have resting HR ≥70 bpm, which has been associated with an
overall worse health status, more frequent angina, and ischemia.26
Sex- and age-related differences have also been identified. Women
were more likely to have angina but less likely to have undergone
revascularization procedures; and patients ≥75 years’ old were less
often treated with β-blockers, ASA, and ACEIs than were patients
≤65 years’ old.27 However, after 1-year follow-up, there was no clear
difference in age-adjusted outcomes between men and women with
stable CAD.28 Compared with normal renal function, chronic renal
insufficiency was associated with a lower use of evidence-based
medications for secondary prevention, including antiplatelet drugs,
statins, β-blockers, and ACEIs.29
In patients with atrial fibrillation within CLARIFY, anticoagulants
were markedly underused, whereas antiplatelet therapy was still
widely used, both of which are at odds with contemporary interna-
tional guidelines.30–32
Finally, in patients who underwent noninvasive testing, the pres-
ence of anginal symptoms (with or without ischemia) appeared to be
associated with a higher risk of adverse CV outcomes than ischemia
per se.33 An additional finding of that analysis was that approximately
70% of events occurred in patients with no evidence of myocardial
ischemia on noninvasive testing, indicating that focusing the manage-
ment of stable CAD solely on the prevention or treatment of
TABLE 3 Baseline medications
All CLARIFY
Patients,
n = 32 703
Prior MI >3
Months Ago,a









n = 7544 (23.1%)
History of PCI or
CABG >3 Months
Ago,a n = 22 836
(69.8%)
ASA 28 687 (87.8) 16 806 (89.1) 17 652 (88.3) 6548 (86.8) 20 298 (88.9)
Thienopyridine 8881 (27.2) 5179 (27.5) 6244 (31.3) 1913 (25.4) 7217 (31.6)
Other antiplatelets 3023 (9.3) 1659 (8.8) 1984 (9.9) 713 (9.5) 2213 (9.7)
Oral anticoagulants 2670 (8.2) 1501 (8.0) 1614 (8.1) 610 (8.1) 1795 (7.9)
β-Blockers 24 611 (75.3) 14 887 (78.9) 15 317 (76.6) 5435 (72.1) 17 391 (76.2)
Symptoms indicative of intolerance
or contraindication to β-blockers
4718 (14.4) 2822 (15.0) 2816 (14.1) 1278 (17.0) 3078 (13.5)
Ivabradine 3218 (9.8) 1990 (10.5) 1790 (9.0) 1167 (15.5) 1810 (7.9)
Calcium antagonists 8909 (27.3) 4363 (23.1) 5592 (28.0) 2359 (31.3) 6090 (26.7)
Verapamil or diltiazem 1896 (5.8) 898 (4.8) 1135 (5.7) 579 (7.7) 1247 (5.5)
ACEIs 16 895 (51.7) 10 963 (58.1) 10 092 (50.5) 3620 (48.0) 11 548 (50.6)
ARBs 8674 (26.5) 4444 (23.6) 5435 (27.2) 2175 (28.9) 6232 (27.3)
Lipid-lowering drugs 30 191 (92.3) 17 657 (93.6) 18 718 (93.6) 6915 (91.7) 21 415 (93.8)
Long-acting nitrates 7152 (21.9) 4196 (22.2) 4262 (21.3) 2002 (26.6) 4370 (19.1)
Other antianginal agents 4541 (13.9) 2687 (14.2) 2653 (13.3) 1185 (15.7) 2602 (11.4)
Diuretics 9585 (29.3) 5761 (30.5) 5668 (28.4) 2312 (30.7) 6471 (28.4)
Other antihypertensive agents 2251 (6.9) 1209 (6.4) 1341 (6.7) 575 (7.6) 1511 (6.6)
Digoxin and derivatives 828 (2.5) 523 (2.8) 464 (2.3) 204 (2.7) 511 (2.2)
Amiodarone/dronedarone 962 (2.9) 594 (3.1) 614 (3.1) 247 (3.3) 667 (2.9)
Other antiarrhythmics 306 (0.9) 151 (0.8) 185 (0.9) 88 (1.2) 194 (0.9)
NSAIDs 1614 (4.9) 902 (4.8) 897 (4.5) 472 (6.3) 1049 (4.6)
Anti-DM agents 8016 (24.5) 4502 (23.9) 5075 (25.4) 1963 (26.0) 5761 (25.2)
PPIs 8106 (24.8) 4770 (25.3) 5106 (25.5) 2178 (28.9) 5948 (26.1)
Thyroid HRT 1420 (4.3) 738 (3.9) 804 (4.0) 355 (4.7) 957 (4.2)
HRT in postmenopausal women 99 (0.3) 44 (0.2) 52 (0.3) 37 (0.5) 59 (0.3)
ED 529 (1.6) 329 (1.7) 340 (1.7) 152 (2.0) 367 (1.6)
Reimbursement of CV agents
Full 12 792 (39.2) 7324 (38.9) 7412 (37.2) 3113 (41.4) 9134 (40.1)
Partial 12 318 (37.7) 7114 (37.8) 8061 (40.4) 2678 (35.6) 8992 (39.5)
None 7521 (23.0) 4392 (23.3) 4478 (22.4) 1721 (22.9) 4654 (20.4)
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin II receptor blockers; ASA, acetylsalicylic acid (aspirin); CABG, coronary
artery bypass grafting; CLARIFY, Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease; CV, cardiovascular;
DM, diabetes mellitus; ED, erectile dysfunction; HRT, hormone replacement therapy; MI, myocardial infarction; NSAIDs, nonsteroidal anti-inflammatory
drugs; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor.
Data are presented as n (%).
a Inclusion criteria are not mutually exclusive; some patients may be included in >1 group.
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ischemia does not address the risks that these patients face.33 A
particular focus will be given to these populations (ie, with or
without anginal symptoms and with or without proven ischemia
on noninvasive testing) to try to explain the differences in CV
outcomes.
Despite the size and scope of CLARIFY, the registry is not
without important limitations. First, as with any observational
database, it is difficult to rule out selection biases and confound-
ing. We attempted to improve the representativeness of the
cohort: minimizing the risk of selection bias by drastically limiting
the enrollment period and attempting to balance representation of
each country by targeting a fixed proportion of patients in relation
to each country’s population. Second, although patients were
enrolled in North and Central America, there was no enrollment in
the United States. Third, there was not 100% source data monitor-
ing, but audits were performed in randomly selected sites and data
were reviewed and queried remotely. Finally, events were col-
lected as reported by investigators and there was no central adju-
dication, although a set of short definitions was included in the
case-report forms to assist investigators in defining and identifying
clinical characteristics and outcomes.
5 | CONCLUSION
The CLARIFY Registry will provide a large database of contemporary
international data regarding the characteristics, management, and
outcomes of patients with stable CAD.
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